PTC Therapeutics (NASDAQ:PTCT) CAO Sells $172,983.84 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 2,494 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $172,983.84. Following the completion of the sale, the chief accounting officer directly owned 70,199 shares of the company’s stock, valued at $4,869,002.64. This represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Thursday, January 8th, Christine Marie Utter sold 1,034 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total transaction of $79,049.30.
• On Wednesday, January 7th, Christine Marie Utter sold 1,235 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.45, for a total transaction of $95,650.75.
• On Tuesday, January 6th, Christine Marie Utter sold 1,381 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $106,267.95.

PTC Therapeutics Stock Performance

Shares of PTCT opened at $70.66 on Monday. The company has a 50-day simple moving average of $74.91 and a 200-day simple moving average of $68.14. The firm has a market capitalization of $5.85 billion, a P/E ratio of 9.13 and a beta of 0.48. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The firm had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same period last year, the business earned ($0.85) earnings per share. The firm’s quarterly revenue was down 22.7% compared to the same quarter last year. As a group, equities analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Analyst Upgrades and Downgrades

Several research analysts recently commented on PTCT shares. Citigroup raised their target price on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. The Goldman Sachs Group raised their price objective on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Wells Fargo & Company decreased their target price on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research report on Friday. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research note on Thursday, January 29th. Finally, Bank of America cut their price target on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $80.73.

Hedge Funds Weigh In On PTC Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in shares of PTC Therapeutics during the third quarter worth approximately $97,252,000. Janus Henderson Group PLC grew its position in PTC Therapeutics by 28.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after acquiring an additional 1,077,776 shares during the last quarter. State Street Corp increased its holdings in PTC Therapeutics by 34.2% during the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after purchasing an additional 1,071,343 shares in the last quarter. Toronto Dominion Bank raised its position in PTC Therapeutics by 27.5% in the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock valued at $314,339,000 after purchasing an additional 891,690 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in PTC Therapeutics by 4,013.1% in the fourth quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock worth $62,945,000 after purchasing an additional 808,515 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.